Jackson Wealth Management LLC Has $4.91 Million Position in Boston Scientific Corporation $BSX

Key Points

• Jackson Wealth Management LLC has reduced its holdings in Boston Scientific Corporation by 10.3%, now owning 45,713 shares valued at about $4.91 million.
• Insider trading activity has seen notable sales, including EVP Joseph Michael Fitzgerald selling 50,000 shares for approximately $4.92 million, reducing his position by 21.90%.
• Boston Scientific recently beat quarterly earnings estimates, reporting $0.75 EPS against an expectation of $0.72, along with a revenue of $5.06 billion, marking a 22.8% increase year-over-year.

Jackson Wealth Management LLC reduced its holdings in Boston Scientific Corporation (NYSE:BSX - Free Report) by 10.3% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 45,713 shares of the medical equipment provider's stock after selling 5,248 shares during the period. Jackson Wealth Management LLC's holdings in Boston Scientific were worth $4,910,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. 1248 Management LLC acquired a new stake in Boston Scientific in the 1st quarter valued at $26,000. Y.D. More Investments Ltd acquired a new position in shares of Boston Scientific during the 1st quarter worth about $27,000. Sound Income Strategies LLC increased its stake in shares of Boston Scientific by 90.9% during the 2nd quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider's stock worth $27,000 after purchasing an additional 120 shares during the last quarter. Oliver Lagore Vanvalin Investment Group acquired a new position in shares of Boston Scientific during the 2nd quarter worth about $37,000. Finally, Activest Wealth Management increased its stake in shares of Boston Scientific by 6,216.7% during the 1st quarter. Activest Wealth Management now owns 379 shares of the medical equipment provider's stock worth $38,000 after purchasing an additional 373 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the company's stock in a transaction that occurred on Wednesday, October 1st. The shares were sold at an average price of $98.47, for a total transaction of $4,923,500.00. Following the completion of the sale, the executive vice president owned 178,342 shares of the company's stock, valued at approximately $17,561,336.74. This represents a 21.90% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Yoshiaki Fujimori sold 2,901 shares of the company's stock in a transaction that occurred on Tuesday, July 29th. The stock was sold at an average price of $106.99, for a total transaction of $310,377.99. Following the sale, the director directly owned 2,081 shares of the company's stock, valued at approximately $222,646.19. This trade represents a 58.23% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 174,214 shares of company stock worth $17,972,457. Insiders own 0.50% of the company's stock.

Boston Scientific Stock Performance

NYSE BSX opened at $97.30 on Friday. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49. The company has a market capitalization of $144.17 billion, a P/E ratio of 57.91, a P/E/G ratio of 2.32 and a beta of 0.61. Boston Scientific Corporation has a 12-month low of $80.64 and a 12-month high of $109.50. The firm has a 50-day moving average price of $102.93 and a two-hundred day moving average price of $102.05.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.72 by $0.03. The firm had revenue of $5.06 billion during the quarter, compared to the consensus estimate of $4.89 billion. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The business's revenue for the quarter was up 22.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.62 EPS. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have recently weighed in on BSX. Raymond James Financial boosted their price objective on shares of Boston Scientific from $121.00 to $124.00 and gave the stock a "strong-buy" rating in a research note on Thursday, July 24th. Robert W. Baird upped their price target on shares of Boston Scientific from $123.00 to $128.00 and gave the company an "outperform" rating in a research note on Wednesday. Jefferies Financial Group reiterated a "hold" rating on shares of Boston Scientific in a research note on Monday, July 21st. BTIG Research upped their price target on shares of Boston Scientific from $127.00 to $132.00 and gave the company a "buy" rating in a research note on Wednesday. Finally, Erste Group Bank lowered shares of Boston Scientific from a "buy" rating to a "hold" rating in a research note on Friday. Two analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, Boston Scientific currently has a consensus rating of "Buy" and a consensus price target of $120.79.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.